Invivo Partners is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of €100 million. This new fund underscores Invivo Partners’ commitment to revolutionizing the life sciences sector, particularly at the intersection of advanced therapies, synthetic biology, and artificial intelligence.
Invivo Partners has established a solid track record of successful exits with the acquisitions of Sanifit and Versantis in 2022, and substantial funding rounds recently closed, such as Arthex’s €42M Series B round in May 2023 and Corteria’s €65M Series A in September 2023. Invivo Ventures III is strategically designed to propel the emergent field of synthetic biology, a domain where Invivo has already established a formidable presence through investments in pioneering companies. These investments reflect Invivo’s expertise and belief in the transformative potential of deep tech to address critical healthcare challenges.
With the launch of this new fund, Invivo Partners is delighted to announce the promotion of Laura Rodríguez from Principal to Partner, following a robust tenure in venture capital. With a PhD in Biotechnology and a strong background in oncology gene therapy research, Laura has contributed to the advancement of the biotech sector through her work in tech transfer at the Vall d’Hebron Hospital Research Institute and as a board director for portfolio companies. Laura is committed to fostering the biotech ecosystem, actively engaging as a mentor, evaluator, and board director, contributing significantly to the innovation ecosystem.
The fund’s focus aligns with Invivo’s mission to support early-stage life science companies that are at the forefront of innovation. With a majority of private investors and the backing of significant institutional investors, Invivo Ventures III is poised to make a substantial impact in the life sciences ecosystem.
“In these challenging economic times, this closing speaks volumes about the strength of our investments and our team’s dedication. It’s an absolute privilege to welcome Laura to our partnership; her extraordinary contributions will undoubtedly propel us to new heights. As we embark on this journey, our ultimate goal remains unwavering: to make a meaningful impact on patients’ lives. They are the heart of our mission” said Luis Pareras, Managing Partner.
«The launch of Invivo Ventures III is a natural progression of our commitment to nurturing groundbreaking life science companies. It has been more than 12 years since we started this journey, with more than 15 portfolio companies invested in. With this third fund, we are more optimistic than ever about the potential opportunities awaiting in the field of life sciences.» said Albert Ferrer, Partner.
«I am deeply honored by the promotion to Partner at such a pivotal moment for Invivo Partners. This opportunity to contribute to the building of new companies that push the boundaries of innovation in advanced therapies is a challenge I accept with both gratitude and eagerness.» said Laura Rodríguez, Partner.
Invivo Partners continues to be a beacon of innovation and progress in the venture capital landscape, especially in the early-stage life sciences sector. The firm’s track record of successful investments and its strategic focus on areas like synthetic biology and advanced therapies underscore its commitment to driving meaningful change and progress in healthcare.
About Invivo Partners
Invivo Partners, a Spanish venture capital firm co-founded by Dr. Luis Pareras and Albert Ferrer, invests in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. It has managed so far two funds supported by a majority of private investors and a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Global, the Catalan Finance Institute, the Valencia Institute of Finance and the
Barcelona City Council.
cloud technology axon
UNILABS es el principal proveedor europeo de servicios de diagnóstico...
